Introduction {#s1}
============

The global prevalence of end-stage renal disease (ESRD) continues to climb. In 2016, 19,301 kidney transplants were performed in the United States, and approximately five times as many were performed worldwide[^1^](#fn1){ref-type="fn"}^,^[^2^](#fn2){ref-type="fn"}. Due to improvements in surgical techniques, immunosuppression protocols, and clinical management of post-transplant complications, the five-year graft survival rates for kidneys obtained from deceased and living donors reached highs of 75.3% and 85.3%, respectively ([@B11];[@B54]; [@B62]). However, the prevalence of ESRD cases in the US has continued to rise by ∼20,000 cases per year over the past three decades, creating an increased need for kidney allografts^1^. This increase is believed to be due primarily to worsening diets and other modifiable factors associated with Western lifestyle but also to an increase in the longevity of pre-transplant ESRD cases.

It is well established that genetic factors contribute to the development and progression of specific types of chronic kidney disease (CKD), yet many previous studies have been limited in scope due to small sample sizes and genotyping strategies ([@B3]; [@B38]; [@B44]; [@B43]; [@B58]). Studies of families with severe phenotypes of diseases, such as Alport's Syndrome and Fabry Disease, have significantly contributed to the understanding of the genetic characteristics of these conditions ([@B13]; [@B24]; [@B37]). However, milder forms of these diseases and their role in the development of ESRD have yet to be explored in great depth.

Genome-Wide Genotyping Arrays {#s1_1}
-----------------------------

Array based genome-wide genotyping from diverse patient populations facilitates very precise ancestry determination using methods such as principal component analysis ([@B7]; [@B30]). Genome-wide association studies (GWAS) among patients with CKD have detected both rare and common genetic variants significantly associated with estimated glomerular filtration rate (eGFR) decline and microalbuminuria, some of the strongest predictors of CKD outcomes, despite \>80% of GWAS participants having eGFRs in the normal range ([@B4];[@B5];[@B49]; [@B14]; [@B43]; [@B32]).

The findings of genome-wide studies may also provide new therapeutic targets to slow the progression of CKD to ESRD, which may delay or impact the need for transplantation in some patient populations ([@B66]; [@B23]). For example, nephropathic cystinosis, a rare autosomal recessive disease, is caused by a 57-kb deletion in the *CTNS* gene in ∼75% of patients of European ancestry and progresses to ESRD if left untreated ([@B6]). However, treatment with oral cysteamine by five years of age has been found to significantly decrease the prevalence and delay the onset of ESRD ([@B6]). Additionally, at least 38 genes have been associated with the development of genetic focal segmental glomerulosclerosis (FSGS), some of which have been shown to be responsive to glucocorticoid treatment ([@B50]). GWAS findings can also provide insight into the biology of ESRD, helping to remove diagnostic heterogeneity. The two *APOL1* risk alleles (G1 and G2) found in high frequency in sub-Saharan African populations and strongly associated with FSGS and HIV nephropathy were found to activate protein kinase R, thus inducing glomerular injury and proteinuria ([@B25]; [@B31]; [@B42]). Overall, results from genome-wide screening can enable physicians to provide accurate genetic diagnoses for the primary cause of ESRD, enabling timely and effective therapeutic managemenvwt and aiding in the evaluation of family members as living donors ([@B56]).

### Whole-Exome and Whole-Genome Sequencing {#s1_1_1}

In the last decade, whole-exome sequencing (WES) and whole-genome sequencing (WGS) approaches have been used very successfully to discover and diagnose genetic disorders in a clinical context ([@B34]; [@B27]; [@B63];[@B16]). WES typically yields sufficient depth of sequencing coverage across ∼95% of nucleotides in coding regions captured and has been used to diagnose rare high penetrant, Mendelian disorders, discover common variants, and identify causal mutations in cancer ([@B20]; [@B68]). WES has recently been implemented as a first-line diagnostic tool in clinical medicine. In a study on fetuses with congenital anomalies of the kidney and urinary tract (CAKUT), pathogenic variants were discovered in 13% of cases ([@B28]). WES has also been applied to adult-onset CKD and ESRD, in which ∼10% of cases are caused by Mendelian mutations ([@B65]; [@B27]; [@B16]). In a cohort of \>3,000 patients with advanced CKD and ESRD ascertained for a clinical trial, WES identified diagnostic variants in 9.3% of patients encompassing 66 monogenic disorders ([@B16]). Of the 343 detected variants, 141 (41%) had not been previously reported as pathogenic. Additionally, diagnostic variants were identified in 17.1% of individuals with nephropathy of unknown origin, altering medical management by initiating multidisciplinary care, prompting referral to clinical trials, and guiding donor selection for transplantation ([@B16]). However, it should be noted that many CKD studies using WES have struggled to obtain adequate control populations. iGeneTRAiN has a large pool of healthy donors (in kidney and in other organs), which represents a strong advantage for our study designs.

WGS is the most comprehensive approach for the detection of inherited variants due to more complete genome-wide coverage, although there are additional challenges compared to WES. WGS can capture single nucleotide genetic variants, small Insertions and Deletions (Indels), and Copy-Number Variants (Cnvs) throughout the human genome. Although it has a higher cost per sample and can be more difficult to analyze than wes, greater diagnostic yields are evident in patients with negative or inconclusive wes results ([@B2]; [@B33]). WGS has been shown to identify a diagnostic genetic variant in ∼10--50% of individuals with a suspected genetic disorder, depending on the clinical study population(S-) being screened ([@B60]; [@B16]; [@B35]).

### International Genetics and Translational Research in Transplantation Network {#s1_1_2}

Despite technological advances that enable research to be carried out on a genome-wide scale, many studies have been hindered by small sample sizes in single transplant sites, as well as the vast number of complex donor and recipient clinical covariates and disease-related phenotypes observed in transplantation. The International Genetics & Translational Research in Transplantation Network (iGeneTRAiN) is a multi-site consortium that encompasses \>45 genetic studies with ∼51,210 solid-organ transplant subjects ([@B21]). The iGeneTRAiN consortium aims to discover and validate solid organ transplant related genetic factors and post-transplant complications, including primary disease, disease recurrence, drug- and cardio-metabolic related adverse events, and different forms of allograft rejection ([@B21]). Of the iGeneTRAiN samples, 54% (n = 28,015) are from kidney transplant cohorts and include 17,742 (63.3%) recipients and 10,273 (36.7%) donors. The genotyped donor DNA provides control samples for all iGeneTRAiN studies, a large advantage over previously published genetic studies.

The iGeneTRAiN consortium designed and developed a genome-wide genotyping array, the "TxArray," which was enriched with content relating to known or putative transplant-specific genetic associations ([@B30]). The TxArray version 1 contains ∼782,000 genetic markers, with tailored transplant-specific content to capture variants across *HLA*, *KIR*, loss-of-function, pharmacogenomic, and cardio-metabolic loci. The array also contains extensive overlap with the UK Biobank Axiom^®^ Array and the Axiom Biobank Genotyping Array, enabling future joint studies or meta-analyses using conventional, hypothesis-free GWAS approaches ([@B30]).

The first wave of iGeneTRAiN kidney cohorts had a wide geographic representation with participants from various sites in the United States, Canada, Australia, The Netherlands, United Kingdom, and Ireland, including both adult and pediatric sites ([**Figure 1**](#f1){ref-type="fig"}). Over the past few years, many genetic discoveries have been made within the iGeneTRAiN cohorts related to kidney, heart, liver, and lung transplants ([@B39]; [@B15]; [@B55]; [@B18]; [@B40]; [@B56]; [@B41]; [@B48]). The Wellcome Trust Case Control Consortium (WTCCC) carried out the first large-scale GWAS with both kidney transplant donor and recipient DNA with the goal of identifying genetic variants, in addition to the *HLA* regions, that significantly contribute to long- and/or short-term renal allograft survival ([@B18]). No non-*HLA* signals were observed at genome-wide significance in this initial study, illustrating the need for harmonization of larger, well-phenotyped kidney transplant cohorts. In addition to the previously discovered common loss-of-function variant *CYP3A5\*3* allele (rs776746), the Deterioration of Kidney Allograft Function (DeKAF) Trial identified two *CYP3A5* variants, rs10264272 and rs41303343, and one *CYP3A4* variant, rs35599367, that explain additional portions of variance observed in dose-adjusted tacrolimus (TAC) through blood concentrations for African American (AA) and European ancestry (EA) kidney transplant recipients, respectively ([@B12]; [@B22]; [@B39]; [@B40]). These findings illustrate the utility of genome-wide studies when determining immunosuppression therapy regimens post-transplant, potentially contributing to improvements in renal allograft survival. Another iGeneTRAiN study showed that GWAS performed in nontransplant settings can predict post-transplant complications. Polygenic risk scores calculated from non-melanoma skin cancer (NMSC) GWAS in the general population predicted risk of and time to post-transplant NMSC and added additional predictive value beyond that explained by clinical variables ([@B57]).

![Geographical Map of Current iGeneTRAiN Kidney Sites and Sub-sites.](fgene-10-01084-g001){#f1}

### Ongoing iGeneTRAiN Kidney Genome-Wide Studies {#s1_1_3}

Recently, additional kidney transplant cohorts from Austria, Belgium, Germany, France, Italy, The Netherlands, Saudi Arabia, South Korea, Switzerland, and additional United States sites have joined iGeneTRAiN. This greatly increases ancestral diversity of recipients and donors, as well as statistical power to detect transplant related genetic variants that impact primary disease and transplant outcomes ([**Figure 1**](#f1){ref-type="fig"}). Our large sample sizes are enabling us to investigate both donor and recipient characteristics that effect ESRD cause, treatment, and transplant-related outcomes.

Where available, we obtained formal clinical diagnoses of primary cause of ESRD, organized into disease categories of diabetic, arteriopathic, glomerular, acute kidney injury, infective and obstructive nephropathy, congenital, familial, toxic nephropathy, and malignancies, for all iGeneTRAiN kidney cohort subjects ([**Table 1**](#T1){ref-type="table"}). With these datasets, we are working to increase our understanding of the genetic underpinnings of ESRD and primary disease through single nucleotide polymorphism (SNP) based GWAS, copy number variant (CNV) screening, donor-recipient properties, allogenicity, and transplant outcomes.

###### 

Primary cause of ESRD in iGeneTRAiN kidney cohorts.

  Primary Cause of ESRD                       University of Pennsylvania   Transplant-LINES   BioMARGIN^‡^   Swiss Transplant Cohort Study^†^   WTCCC-3^†^    Go-CAR        Columbia Transplant Biobank   Torino Transplant Cohort^‡^   Rotterdam^‡^   DeKAF\*       Gen03\*       Scripps   Leiden\*     Vienna        Vanderbilt   Seoul^†,‡^
  ------------------------------------------- ---------------------------- ------------------ -------------- ---------------------------------- ------------- ------------- ----------------------------- ----------------------------- -------------- ------------- ------------- --------- ------------ ------------- ------------ -------------
  **Diabetic nephropathy**                    310 (26.8%)                  51 (4.0%)          115 (8.5%)     116 (7.4%)                         186 (7.3%)    219 (37.2%)   176 (15.6%)                   22 (3.3%)                     -- (17.0%)     553 (28.5%)   178 (22.8%)   --        22 (25.0%)   113 (12.8%)   --           240 (20.9%)
  **Arteriopathic renal disease**             202 (17.5%)                  104 (8.2%)         67 (4.9%)      183 (11.6%)                        111 (4.4%)    109 (18.5%)   123 (10.9%)                   36 (5.4%)                     -- (13.0%)     132 (6.8%)    43 (5.5%)     --        --           88 (10.0%)    --           244 (21.3%)
  **Glomerular disease**                      340 (29.4%)                  401 (31.6%)        329 (24.2%)    433 (27.5%)                        482 (19.0%)   111 (18.9%)   431 (38.3%)                   198 (29.7%)                   -- (20.0%)     446 (23.0%)   226 (29.0%)   --        14 (15.9%)   296 (33.6%)   --           251 (21.9%)
  **AKI**                                     3 (0.3%)                     1 (0.1%)           3 (0.2%)       0 (0.0%)                           8 (0.3%)      0 (0.0%)      5 (0.4%)                      2 (0.3%)                      -- (4.0%)      --            --            --        --           4 (0.5%)      --           0 (0.0%)
  **Infective and obstructive nephropathy**   31 (2.7%)                    107 (8.4%)         79 (5.8%)      85 (5.4%)                          203 (8.0%)    22 (3.7%)     17 (1.5%)                     87 (13.1%)                    -- (6.0%)      --            --            --        --           56 (6.4%)     --           6 (0.5%)
  **Congenital diseases**                     19 (1.6%)                    68 (5.4%)          57 (4.2%)      40 (2.5%)                          26 (1.0%)     14 (2.4%)     58 (5.2%)                     31 (4.7%)                     -- (3.0%)      --            --            --        --           18 (2.1%)     --           0 (0.0%)
  **Familial hereditary renal diseases**      143 (12.4%)                  235 (18.5%)        245 (18.0%)    327 (20.8%)                        361 (14.2%)   67 (11.4%)    145 (12.9%)                   110 (16.5%)                   -- (14.0%)     308 (15.9%)   123 (15.8%)   --        52 (59.1%)   147 (16.7%)   --           25 (2.2%)
  **Toxic nephropathy**                       2 (1.7%)                     15 (1.2%)          19 (1.4%)      46 (2.9%)                          16 (0.6%)     18 (3.1%)     31 (2.8%)                     9 (1.4%)                      -- (1.0%)      --            --            --        --           25 (2.8%)     --           4 (0.4%)
  **Neoplasms**                               5 (0.4%)                     6 (0.5%)           21 (1.5%)      0 (0.0%)                           20 (0.8%)     2 (0.3%)      6 (0.5%)                      5 (0.8%)                      -- (3.0%)      --            --            --        --           14 (1.6%)     --           0 (0.0%)
  **Other disease**                           50 (4.3%)                    59 (4.6%)          64 (4.7%)      344 (21.9%)                        165 (6.5%)    12 (2.0%)     9 (0.8%)                      6 (0.9%)                      -- (10.0%)     432 (22.3%)   166 (21.3%)   --        --           17 (1.9%)     --           0 (0.0%)
  **ESRD of unknown etiology**                29 (2.5%)                    168 (13.2%)        161 (11.8%)    0 (0.0%)                           0 (0.0%)      14 (2.4%)     125 (11.1%)                   160 (24.0%)                   -- (9.0%)      --            --            --        --           100 (11.4%)   --           185 (16.1%)
  **Missing information**                     4 (0.4%)                     56 (4.4%)          200 (14.7%)    0 (0.0%)                           966 (38.0%)   0 (0.0%)      0 (0.0%)                      0 (0.0%)                      -- (0.0%)      67 (3.5%)     44 (5.6%)     --        --           2 (0.2%)      --           193 (16.8%)
  **Total**                                   **1156**                     **1271**           **1360**       **1574**                           **2544**      **588**       **1126**                      **666**                       **--**         **1938**      **780**       **--**    **88**       **880**       **--**       **1148**

\*Data includes Caucasian only ancestry. ^‡^Recently added iGeneTRAiN kidney cohort.

^†^National level iGeneTRAiN kidney cohort. See [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"} for full breakdown of primary cause of ESRD.

Copy Number Variant Screening in iGeneTRAiN Cohorts {#s1_2}
---------------------------------------------------

Genome-wide genotyping arrays are well established as an effective means for identification of known and novel CNVs ([@B51]; [@B1]; [@B61]). CNV screening within iGeneTRAiN subjects is of major interest for both assessing the genetic architecture of primary disease and for allogenicity studies. iGeneTRAiN has developed an extensive loss-of-function (LoF) pipeline which includes haplotype phasing of over 10 million directly genotyped and imputed variants. We are particularly interested in two copy LoF (by single-nucleotide variants and/or CNVs) and integration of one or two copy LoF variants for donor-recipient interaction analyses, for association with time-to-rejection and graft loss events ([@B21]).

CNV screening in *a priori* regions for primary disease has been performed in iGeneTRAiN cohorts. For example, we performed CNV screening in patients with nephronophthisis (NPH), the most common genetic cause of ESRD in children and often caused by homozygous *NPHP1* full gene deletions ([@B29]; [@B19]; [@B64]). In iGeneTRAiN, we previously examined this region in a subset of iGeneTRAiN studies for adult-onset ESRD (n = 5,606 patients). Of the subjects analyzed, 26 patients showed homozygous *NPHP1* CNV deletions. Interestingly only 12% of these patients were previously diagnosed as having NPH and many presented with ESRD later in adulthood ([@B56]). Thus, using the two copy gene loss of *NPHP1* from GWG arrays to ascertain NPH status and examine NPH-related information in iGeneTRAiN studies, including accuracy of case-ascertainment and age-of-onset, shows a strong proof-of-principle for use in other high penetrant autosomal recessive/dominant cases, and the need for further sequencing for rare single-nucleotide variants in adult-onset ESRD patients. Furthermore, in a recent genome-wide analysis of CNVs in almost 3,000 cases of CAKUT, 45 distinct, known genomic disorders at 37 independent genomic loci were identified in 4% of CAKUT cases, and novel genomic disorders were found in an additional ∼2% of cases ([@B61]). Genome-wide genotyping and imputation using large whole-genome sequencing (WGS) datasets, such as the 1000 genomes project (1KGP), typically cannot identify variants in the most common ancestral populations to a minor allele frequency (MAF) of \<0.005, yet it is often possible to identify rare CNVs using monomorphic or SNP based probes across loci.

Our previous analyses of the Axiom TxArray genome-wide genotyping data was primarily limited to approximately 2,000 *a priori* CNV regions of interest that had specific probes designed onto the TxArray. Initial analyses used an adaption of the BRLMM-P CNV algorithm adapted from algorithms previously used to cluster genotypes across many samples ([@B67]). However, BRLMM-P could only identify up to three clusters and thus was only able to detect 0, 1, and 2 copy deletions. The newer Axiom Analysis Suite 4.0 software allows streamlined, targeted, and *de-novo* whole-genome CNV region analysis[^3^](#fn3){ref-type="fn"}. A major advantage of the newer software is the ability to detect duplications as well as 0, 1, and 2 copy deletions ([**Figure 2**](#f2){ref-type="fig"}).

![**(A)** Copy Number Variant Region Analyses of the *NPHP1* locus using the Axiom Analysis Suite 4.0 to call diploid state (CN=2), one copy deletion state (CN=1), two copy deletion state (CN=0), and duplication state (CN=3). The x-axis shows the chromosomal location on Chromosome 2 while the y-axis shows the standard Log2Ratio intensity. **(B)** In depth illustration of the duplication (CN=3) state.](fgene-10-01084-g002){#f2}

Discussion {#s2}
==========

Genome-wide genotyping studies have become very affordable and streamlined. However, large sample sizes, on the order of 10,000--100,000, are needed in order to detect both rare variants with large contributions and common variants with minor contributions to a specific phenotype(s) ([@B26]). While it is very important to bolster statistical power to detect genetic underpinnings of transplant-related phenotypes by aggregating similar cohorts, great caution must be exercised when combining genotyping and phenotyping datasets, especially as transplant study covariates are very complex and can vary greatly by era and geographical region. iGeneTRAiN does have a unified quality control/quality assurance GWAS pipeline, including adjustment for population-based stratification ([@B21]). Association study analyses do adjust for all known/available study covariates, including patient demographics and clinical characteristics, and we adjust for each transplant site alone to look for confounders. Genome-wide genotyping arrays are generally poor at detecting rarer frequency pathogenic variants, with the exception of medium to large CNVs. Significant advances in genomic technologies and the decreasing cost of WES/WGS efforts over the past several years have made it increasingly feasible to carry out better designed genome-wide studies in a clinical environment ([@B17]). However, there are still significant advantages to having genome-wide genotyping array datasets, as rigorous quality control and quality assurance measures are generally performed on the original DNA, and gender, ancestry, and *HLA* (amino acid imputation) concordance checks can be performed before progressing to WES or WGS pipelines for deeper genetic characterization. GWAS are able to provide insight into genetic risk scores and pathogenic CNVs, as genome-wide variants are covered in conventional genome-wide genotyping arrays ([@B52]; [@B30] [@B36]; [@B56]; [@B57]). For example, a meta-analysis across 36 articles identified three genetic variants that are significantly associated with new onset diabetes after transplantation (NODAT), all of which are also known risk factor variants for Type 2 diabetes. The integration and analysis of large and complex multi-omic datasets has been demonstrated in a number of recent high impact publications, which in general increase, by approximately 10-fold, the statistical power to detect and illustrate functional variants ([@B10]; [@B45]; [@B53]; [@B69]). iGeneTRAiN genomic data can be integrated with results from proteome-, metabolome-, and transcriptome-wide transplant studies to further characterize clinical risks and allow for personalized treatments, as a number of iGeneTRAiN studies have multi-omic datasets/samples ([@B21]).

The advent of single-cell RNA sequencing (scRNASeq) has yielded major insights into the biology of CKD. Expression quantitative trait loci (eQTL) atlases have been generated for glomerular and tubular compartments from human kidney cells. Integrating results from genome-wide studies of CKD with eQTL from scRNAseq as well as known regulatory region maps has been shown to identify novel CKD genes ([@B46]). The Human Cell Atlas project is a major international initiative which aims to create comprehensive reference maps of all human cells to gain fundamental insight into the understanding of human health and will undoubtedly aid in the diagnoses and surveillance of a range of diseases ([@B47]).

Future of iGeneTRAiN Kidney Cohorts Analyses {#s2_1}
--------------------------------------------

As the population of kidney transplant recipients and donors continues to grow in the iGeneTRAiN consortium and as post-transplant outcomes accrue, we will be able to further increase our knowledge of the genetic underpinnings of ESRD, primary disease, and post-transplant outcomes, such as acute rejection and graft loss. These sequencing approaches may provide additional insight into donor-recipient (D-R) interactions that influence graft outcomes. Although it is well established that allelic matches across *HLA* loci impact clinical outcomes post-transplant, there is a paucity of genome-wide research conducted to identify donor-recipient interactions independent of *HLA* ([@B59]; [@B9];[@B58]). One recent iGeneTRAiN kidney D-R study showed decreased allograft survival of recipients with increased D-R kidney transmembrane non-synonymous SNPs (nsSNPs). We further demonstrated that we could detect alloantibodies against customized amino-acid peptides designed with a number of these kidney transmembrane nsSNPs using sera from these patients ([@B48]). Finally, data from all solid-organ transplant studies in the iGeneTRAiN consortium will be utilized in cross-organ studies in order to gain additional insight into the genetics of acute rejection, allograft/patient survival, and pharmacogenomic outcomes.
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